1. Medtech Insight
  2. >>Business
  3. >>R&D
  4. >>Clinical Trials

Apple And J&J Collaborate On Large Atrial Fibrillation Study

 
• By Reed Miller

The Heartline Study is evaluating how the Apple Watch can identify and predict atrial fibrillation while improving cardiovascular outcomes and patients’ adherence to anticoagulant drugs.

girl wears the apple watch while using the iphone 6
• Source: shutterstock.com

Apple Inc. and Johnson & Johnson are now recruiting patients into Heartline, a 150,000-patient “virtual” randomized study designed to evaluate how the Apple Watch can improve patient outcomes by reducing the risk of stroke and detect atrial fibrillation early.

The US Food and Drug Administration cleared an electrocardiogram (ECG) function and photoplethysmography analysis software for the Apple Watch last year, allowing the company to claim that the Apple Watch can detect and notify patients of irregular heart rhythms that could represent atrial fibrillation, which increases the risk of stroke

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Clinical Trials

Axoft Starts Commercializing Soft BCI-Enabling Materials For R&D Use, Aims To Rewrite BCI Playbook

 
• By Marion Webb

After publishing encouraging results from first-in-human trials of its brain-computer interface, Axoft announced plans to sell its BCI-enabling material Fleuron to researchers and private organizations for R&D use. The company sees this as a revenue stream and feedback loop to refine its BCI platform designed for safer, longer-lasting brain implants.

Peerbridge Bets On At-Home Heart Monitoring With Rechargeable, Longer-Lasting ECG Patch

 
• By Marion Webb

Peerbridge Health is preparing to submit its next-generation ECG patch, CorMDx, for US FDA clearance this quarter, with plans to launch in the second half of 2025. The rechargeable device is designed for continuous, real-time heart monitoring from the hospital to home, aiming to detect early signs of heart failure and reduce emergency room visits.

Subsense Develops Nonsurgical, Nanoparticle-Based Brain-Computer Interface For Neurological Disorders

 
• By Marion Webb

Neurotechnology start-up Subsense came out of stealth with $17m in seed funding to develop a nonsurgical, nanoparticle-based brain-computer interface. Medtech Insight spoke with the firm’s new neurotech lead Cyril Eleftheriou about the technology and its potentially wide applications for treating Parkinson’s, epilepsy, inner speech decoding, and more.

AAOS 2025 Orthopedic Roundup: J&J Velys UKA, Stryker Mako 4, Materialise, Canary Medical

 
• By Marion Webb

At AAOS, orthopedics players showcased their latest robotic-assisted platforms, power tools, 3D printed technologies and software offerings. This article brings you highlights from interviews Medtech Insight conducted on site with representatives from J&J, Stryker, Materialise and Canary Medical.

More from R&D